



HOKKAIDO UNIVERSITY

Title	Morbidity and mortality in antiphospholipid syndrome based on cluster Analysis : a 10-year longitudinal cohort study
Author(s)	Ogata, Yusuke; Fujieda, Yuichiro; Sugawara, Masanari et al.
Citation	Rheumatology, 60(3), 1331-1337 https://doi.org/10.1093/rheumatology/keaa542
Issue Date	2021-03
Doc URL	https://hdl.handle.net/2115/84220
Rights	This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record Yusuke Ogata, Yuichiro Fujieda, Masanari Sugawara, Taiki Sato, Naoki Ohnishi, Michihito Kono, Masaru Kato, Kenji Oku, Olga Amengual, Tatsuya Atsumi, Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study is available online at: https://doi.org/10.1093/rheumatology/keaa542
Type	journal article
File Information	Rheumatology 60 1331-1337.pdf



Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study

Yusuke Ogata*, Yuichiro Fujieda*, Masanari Sugawara, Taiki Sato, Naoki Ohnishi,
Michihito Kono, Masaru Kato, Kenji Oku, Olga Amengual, and Tatsuya Atsumi.

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and
Graduate School of Medicine, Hokkaido University, Sapporo, Japan

*Yusuke Ogata and Yuichiro Fujieda contributed equally to this study.

Corresponding author:

Yuichiro Fujieda

N15 W7, Kita-ku, 060-8638 Sapporo, Japan

E-mail address: edaichi@med.hokudai.ac.jp

Telephone number: +81-11-706-5913

Fax number: +81-11-706-7710

Running title: Morbidity and mortality of Japanese APS patients

Funding

No specific funding was received to carry out the work described in this manuscript

Conflict of interest

TA reports personal fees from Chugai, during the conduct of the study; grants and personal fees from Astellas, grants and personal fees from Takeda, grants and personal fees from Mitsubishi Tanabe, grants and personal fees from Chugai, grants and personal fees from Pfizer, grants from Daiichi Sankyo, grants from Otsuka, personal fees from Eisai, personal fees from AbbVie, outside the submitted work. M.Kato has received research grants from AbbVie, Actelion, and GlaxoSmithKline and speaking fees from Eli Lilly. M. Kono has received research grants from GlaxoSmithKline plc, Mitsubishi Tanabe, Astellas, Sanofi, Taisho Pharmaceutical, and Taisho Pharmaceutical, outside the submitted work. The other authors state that they have no conflict of interest.

Keywords

Antiphospholipid syndrome (APS), morbidity, mortality, cardiovascular risks, history of arterial thrombosis, cluster analysis

Abstract

OBJECTIVE: To identify a group with poor prognosis and clarify its characteristics among patients with antiphospholipid syndrome (APS) using cluster analysis.

METHODS: This is a longitudinal retrospective cohort study of APS patients. Cluster analysis was performed to classify the patients using clinical data and the profile of antiphospholipid antibody (aPL). Events were defined as thrombosis, severe bleeding, and mortality.

RESULTS: A total of 168 APS patients were included. Cluster analysis classified the patients into three groups; Cluster A (n=61): secondary APS, Cluster B (n=56): accumulation of cardiovascular risks and arterial thrombosis, Cluster C (n=61): triple positivity of aPL and venous thrombosis. Cluster B showed significantly high frequency of the events and high mortality compared with the other clusters (P = 0.0112 for B vs. A and P=0.0471 for B vs. C).

CONCLUSION: Using cluster analysis, we clarified the characteristics of APS patients with poor prognosis. Risk factors for cardiovascular disease may further increase events in APS patients.

1 **Introduction**

2 Antiphospholipid syndrome (APS) is an autoimmune disease characterized by
3 thrombotic events and pregnancy complications associated with persistently positive
4 antiphospholipid antibodies (aPL) (1), including lupus anticoagulant (LA), anti-
5 cardiolipin antibodies (aCL) and anti- β 2GlycoproteinI antibodies (a β 2GPI). Other
6 non-criteria aPL, particularly phosphatidylserine-dependent anti-prothrombin antibodies
7 (aPS/PT) and antibodies against domain I of β 2GPI have also been reported to be
8 related with APS manifestations (2). The persistent presence of aPL represents a
9 thrombotic risk in APS which can be stratified according to the aPL profile (3).

10 APS patients with high-risk aPL profile have a high rate of thrombotic recurrences
11 regardless of antithrombotic therapy (4). In the European League Against Rheumatism
12 (EULAR) recommendations for the management of APS, high-risk aPL profiles were
13 defined as the presence of LA, the presence of double or triple aPL positivity, or the
14 presence of persistently high aPL titres (3).

15 To assess the thrombotic risk in APS, aPL score (aPL-S) and Global APS score
16 (GAPSS) were developed. The aPL-S is a quantitative marker that represents the

17 individual aPL profile and aPL-S ≥ 30 is a considerable risk factor for the development
18 of thrombosis (5). GAPSS is a tool to calculate the relative risk of each aPL for vascular
19 thrombosis or pregnancy morbidity. GAPSS >16 has been reported as an independent
20 risk factor for future thrombotic events (6). However, a prognosis assessment with the
21 risk stratification has not yet been reported in patients with APS. The characteristics of
22 APS patients in addition to the aPL profile might contribute to the poor outcomes.
23 Accordingly, adequate prognosis assessment should be established in patients with APS
24 using the integrate information including aPL profile, clinical information and
25 complications.

26 Cluster analysis is a statistical method that identifies subgroups as defined by multiple
27 characteristics. Recently, cluster analysis has been applied to identified clinical and
28 laboratory characteristics in patients with APS (7) . The subgroups of patients are
29 determined by a hierarchical cluster analysis from the multiple correspondence
30 according to clinical and laboratory characteristics. The use of cluster analysis could
31 visualise the accurate categorisation to evaluate the prognosis.

32 In this study, we aim to identify the group with the poor prognosis in Japanese
33 patients diagnosed with APS based on cluster analysis.

34

35 **Methods**

36 **Patients and methods**

37 This retrospective study has been conducted in a single centre at Hokkaido University
38 Hospital in Sapporo, and in accordance with ethical principles of the Declaration of
39 Helsinki and Good Clinical Practice guidelines approved by Hokkaido University
40 Hospital ethics committee (approval number: 017-0354).

41 The study included patients diagnosed with APS between April 1990 and May 2019
42 according to the Sydney revised Sapporo criteria for definite APS (8). Medical reports
43 were carefully retrospectively reviewed and clinical/laboratory data extracted. The
44 coexistence of systemic lupus erythematosus (SLE) was diagnosed according to the
45 American College of Rheumatology (ACR) revised criteria (9). All treating physicians
46 were board-certified rheumatologists by the Japan College of Rheumatology, and the
47 therapeutic regimen administered following the corresponding APS guidelines. Patients

48 who were followed-up for less than 2 years were excluded. Risk factors for arterial
49 thrombosis including hypertension, diabetes mellitus, dyslipidaemia and smoking were
50 recorded at the start of the observation period. Cardiovascular risks included
51 hypertension, dyslipidaemia, diabetes mellitus, smoking and the aPL-S \geq 30.

52

53 **Antiphospholipid antibody testing**

54 IgG and/or IgM aCL(10), IgG and/or IgM a β 2GPI (11), IgG and/or IgM aPS/PT(12)
55 were evaluated by enzyme-linked immunosorbent assay as described previously. For the
56 detection of LA, the guidelines recommended by the Subcommittee for Standardization
57 of the International Society on Thrombosis and Haemostasis were followed (13) .
58 Antiphospholipid antibodies were assayed in all the patients at the first visit to the
59 autoimmune outpatient clinic and at least a second time, separated by at least twelve
60 weeks. Triple positive aPL was defined according to a previous report(3) as positive for
61 LA, IgG/IgM aCL and IgG/IgM a β 2GPI.

62

63 **Cluster analysis**

64 We applied a hierarchical cluster analysis at the time of diagnosis. We determined
65 APS patients aggregating into different groups sharing common characteristics using
66 the following variables : age at APS onset, aPL-S, sex, SLE, hypertension,
67 dyslipidaemia, diabetes mellitus, three or more cardiovascular risks, history of arterial
68 thrombosis, history of venous thrombosis, positivity for LA, IgG/IgM aCL, IgG/IgM
69 a β 2GPI and/or IgG/IgM aPS/PT. Euclidean distance and the Ward agglomerative
70 method were applied. Each variable is considered as a single cluster and combined with
71 a neighbouring variable determined by the Euclidean distance. A dendrogram showed
72 the process of clustering and the distance between the cluster. To identify the ideal
73 number of clusters, we decided to three clusters with reference to the dendrogram
74 (Supplement Figure1A and 1B). Kaplan-Meier analysis and multiple comparisons were
75 performed in these clusters.

76

77 **Endpoints**

78 The endpoint was set as event-free survival. The event was defined as thrombosis in
79 either arterial or venous territories, severe bleeding events or death. The observation

80 period of each patient was established as the baseline when diagnosed with APS, and to
81 end either at the time of an event or at the end of the observation. The presence of
82 thrombosis was confirmed by imaging studies, and severe bleeding was defined as
83 bleeding episodes that required hospitalisation and/or blood transfusion.

84

85 **Statistical analysis**

86 Categorical variables were described as counts and percentages. Continuous variables
87 were expressed as median and quartiles. Fisher exact test was used for qualitative data
88 analysis. Multiple comparisons were analysed by Kruskal-Wallis test. Kaplan-Meier
89 curves were applied to estimate the rates of mortality and events. In all statistical
90 analyses, $p < 0.05$ was taken to indicate statistical significance. All statistical analyses
91 were performed using JMP® Pro 14.2.0 (SAS Institute Inc., Cary, North Carolina,
92 USA).

93

94 **Results**

95 **Baseline Characteristics of each cluster**

96 A total of 168 APS patients were recruited. Demographic, clinical and laboratory data
97 from all patients are summarised in Table 1. The cohort comprised 144 females and 24
98 males, median age at disease onset was 39 (range 29.5-55) years old and the median
99 observation periods 10 (5-15) years. Cluster analysis classified the 168 patients into
100 three groups.

101

102 **Cluster A: secondary APS**

103 Cluster A included 61 patients (36 % of the total cohort) and 72% of patients had SLE.
104 The median observation period was 8 years. One death (1.6 %) and 16 events (26 %)
105 occurred during the observation period. Cluster A was categorized as a secondary APS
106 group.

107

108 **Cluster B: accumulation of cardiovascular risks and arterial thrombosis**

109 Cluster B included 56 patients (33.3 % of the total cohort) older than those in other
110 groups. These patients had the highest rate of cardiovascular risks, such as hypertension,
111 dyslipidaemia diabetes mellitus. The characteristics of this cluster was the high

112 prevalence of arterial thrombosis. The median observation period was 9 years. Eight
113 deaths (14 %) and 28 events (50 %) occurred during the observation period. Cluster B
114 was categorised as high-risk thrombosis and arterial thrombosis group.

115

116 **Cluster C: triple positive aPL and venous thrombosis**

117 Cluster C included 51 patients (30.4 % of the total cohort) and these patients had a
118 high rate of triple positive aPL. The median observation period was 14 years. Five
119 deaths (9.8 %) and 21 events (41 %) occurred during the observation periods. Cluster C
120 was categorised as triple positive aPL and venous thrombosis group.

121

122 **All events free survival: thrombosis, severe bleeding or death**

123 The events occurred in 65 patients during the observation period and details of the
124 events are summarized in Table 2. In Kaplan-Meier analysis, 5 and 10-year events free
125 survival rates in APS patients were 81.7 % and 64.7 %, respectively (Figure 1A). In
126 cluster analysis, cluster B had a significantly higher event rate (5.56 per 100 patients-
127 years) than the other clusters (P = 0.0112: log-rank test) (Table2 and Figure 1B).

128

129 **Event free survival: thrombosis**

130 The thrombosis occurred in 47 patients including 37 of arterial thrombosis and 10 of
131 venous thrombosis during the observation period. The rate of thrombosis was 2.8 per
132 100 patient-years. The Kaplan-Meier analysis of cluster A, B and C showed 10-year
133 survival rates of 75.5%, 62.9% and 83.5%, respectively. There was not any statistically
134 significant difference among the three clusters. (P = 0.119: log-rank test) (Table2 and
135 Figure2A). A subanalysis of arterial and venous thrombosis also showed no differences
136 for developing thrombosis among the three clusters, respectively (arterial thrombosis
137 P=0.10, venous thrombosis P=0.17).

138

139 **Event free survival: severe bleeding**

140 The severe bleeding occurred in 9 patients during the observation period. Severe
141 bleeding rate was 0.54 per 100 patient-years. In Kaplan-Meier analysis of each cluster,
142 10-year survival rates were 98.3%, 92.2% and 92.3%, respectively. No statistically

143 significant difference was recorded among the three clusters, (P = 0.142: log-rank test)
144 (Table2 and Figure2B).

145

146 **Event free survival: death**

147 The deaths occurred in 14 patients during the observation period. Mortality was 0.83 per
148 100 patient-years. Kaplan-Meier analysis revealed 10-year overall survival rates of
149 100%, 83.2 % and 95.5 %, respectively. In cluster analysis, cluster B had significantly
150 higher mortality compared to the other clusters,1.59 per 100 patients-years, (P = 0.047:
151 log-rank test) (Table 2 and Figure 2C).

152

153 **Discussion**

154 To the best of our knowledge, this retrospective study was the first trial to evaluate the
155 10-year event-free survival rate of the patients with APS based on cluster analysis. The
156 clustering classified APS patients into three subgroups as follows; “secondary APS”
157 “accumulation of cardiovascular risks and arterial thrombosis” or “triple aPL positive
158 and venous thrombosis”. This clustering was different from that reported previously

159 based on serological data (7). The clustering used in our study combines serological and
160 clinical follow-up data.

161 Cluster B categorised as “accumulation of cardiovascular risks and arterial
162 thrombosis” group. Multiple risk factors for cardiovascular disease including
163 hypertension, dyslipidaemia and diabetes mellitus are recognised as risk factors for
164 thrombosis (14, 15). Cluster B had higher risk of events than cluster A and C, the
165 former having SLE as another thrombotic risk (16, 17) and the latter triple positive aPL
166 (18, 19). In addition, Cluster B showed the highest mortality in parallel with the
167 increased number of the events. The 10-year survival rates in our cohort (92.7%) was
168 similar to that reported in the European APS cohort (90.7%) (2). The major causes of
169 death, as well as the rate of thrombosis and serious bleeding events were similar
170 between two cohorts. The bias related to different ethnic backgrounds might be lower in
171 our study. To exclude age biased, multivariate analysis including age was performed
172 (Supplement Table3). Cox's proportional hazards model confirmed the significance of
173 high rate of events in a three or more cardiovascular risks and arterial thrombosis. Given
174 these evidences, the accumulation of the thrombotic risks would contribute to the higher

175 incidence of events and mortality. It is, hence, important to control these vascular risk
176 factors, especially in APS patients with arterial thrombosis.

177 The primary trigger for arterial thrombosis is the rupture of an atherosclerotic plaque.

178 Antibodies against β 2GPI are associated with the autoimmune-mediated

179 atherothrombosis (20). β 2GPI binds oxidized low-density lipoproteins (oxLDL) likely

180 to quench the pro-inflammatory and proatherogenic effects of the oxLDL molecule.

181 APS patients have increasing serum levels of oxLDL/ β 2GPI complexes (21), leading to

182 the activation of monocytes and tissue factor expression (22). Although the aPL profiles

183 in each cluster were not significant difference in our study, cluster B had three or more

184 cardiovascular risks including dyslipidaemia. Therefore, aPL-mediated atherosclerosis

185 might be related with the poor outcome.

186 We applied cluster analysis to identify a group with poor prognosis in patients with

187 APS. In addition, the cluster analysis can clarify the characteristics of the groups

188 regarding the clinical and laboratory data. The ability to identify cluster-associated

189 outcomes can be useful for the management of heterogeneous diseases. Recently,

190 machine learning techniques such as cluster analysis is employed to ensure that

191 populations are similar relative to the outcome of interest in clinical trials of novel
192 therapies(23). The cluster analysis may have potential implications for the management
193 of patients with APS.

194 This study has some limitations. First, due to the study design, a single centre
195 retrospective study, there may be an imbalanced number of patients. Second, the
196 obstetric complication variable was not calculated in the clustering analysis, because
197 males with missing the pregnancy data would affect the clustering analysis. Finally, the
198 treatment variable was excluded in the cluster analysis due to the huge variation among
199 patients.

200 In conclusion, the cluster analysis revealed three groups of APS patients that were
201 significantly different from each other as either “secondary APS” “accumulation of
202 cardiovascular risks and arterial thrombosis” or “triple aPL positive and venous
203 thrombosis”. The group named as “accumulation of cardiovascular risks and arterial
204 thrombosis” had the poorest prognosis among the three groups, indicating that risk
205 factors for cardiovascular disease may further increase events in APS patients.

206 Treatment strategy based on the risk stratification using cluster analysis would be
207 needed in patients with APS.

References

1. Amengual O & Atsumi T (2018) Antiphospholipid syndrome, "the best prophet of the future". *Modern rheumatology* 28(3):409-416.
2. Sciascia S, *et al.* (2014) Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. *Thromb Haemost* 111(2):354-364.
3. Tektonidou MG, *et al.* (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. *Annals of the rheumatic diseases* 78(10):1296-1304.
4. Gebhart J, *et al.* (2015) Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). *Blood* 125(22):3477-3483.
5. Otomo K, *et al.* (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. *Arthritis and rheumatism* 64(2):504-512.
6. Sciascia S, *et al.* (2013) GAPSS: the Global Anti-Phospholipid Syndrome Score. *Rheumatology (Oxford, England)* 52(8):1397-1403.
7. Sciascia S, *et al.* (2019) Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. *Rheumatology (Oxford, England)*.
8. Miyakis S, *et al.* (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 4(2):295-306.
9. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis and rheumatism* 40(9):1725.
10. Devreese KM, *et al.* (2014) Testing for antiphospholipid antibodies

- with solid phase assays: guidance from the SSC of the ISTH. *J Thromb Haemost* 12(5):792-795.
11. Amengual O, Atsumi T, Khamashta MA, Koike T, & Hughes GR (1996) Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. *British journal of rheumatology* 35(12):1239-1243.
 12. Atsumi T, *et al.* (2000) Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. *Arthritis and rheumatism* 43(9):1982-1993.
 13. Pengo V, *et al.* (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost* 7(10):1737-1740.
 14. Ruffatti A, *et al.* (2009) Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. *Annals of the rheumatic diseases* 68(3):397-399.
 15. Burgos PI, McGwin G, Jr., Reveille JD, Vilá LM, & Alarcón GS (2010) Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). *Rheumatology (Oxford, England)* 49(9):1720-1725.
 16. Danowski A, de Azevedo MNL, de Souza Papi JA, & Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. *J Rheumatol* 36(6):1195-1199.
 17. Oku K, *et al.* (2018) Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). *Modern rheumatology* 28(4):642-648.
 18. Atsumi T, *et al.* (2000) Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus

- anticoagulant. *Arthritis and rheumatism* 43(9):1982-1993.
19. Pengo V, *et al.* (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. *J Thromb Haemost* 8(2):237-242.
 20. Matsuura E, Hughes GRV, & Khamashta MA (2008) Oxidation of LDL and its clinical implication. *Autoimmun Rev* 7(7):558-566.
 21. Matsuura E, Kobayashi K, Hurley BL, & Lopez LR (2006) Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. *Lupus* 15(7):478-483.
 22. Otomo K, *et al.* (2016) Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-β2 glycoprotein I antibodies. *Lupus* 25(12):1288-1298.
 23. Ahmad T, *et al.* (2018) Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. *J Am Heart Assoc* 7(8).

Figure Legends

Figure 1

Cumulative event-free survival curves in APS patients by Kaplan-Meier analysis.

(A) Cumulative event-free survival curves in 168 APS patients. Five-year event-free survival rate was 81.7% and 10-year event-free survival rate was 64.7%.

(B) Cumulative event-free survival curves in the three clusters. Five-year event-free survival rates were 82.4%, 74.9% and 87.9%, respectively. Ten-year event-free survival

rates were 74.2%, 48.1% and 73.1%, respectively. Cluster B had statistically significant high rates of incidence of events. (P = 0.0112: log-rank test)

Cluster A: secondary APS, Cluster B: accumulation of cardiovascular risks and arterial thrombosis, Cluster C: triple antiphospholipid antibody (aPL) positive and venous thrombosis.

Figure 2

Cumulative event-free survival curves in APS patients by Kaplan-Meier analysis.

(A) Cumulative thrombosis-free survival curves in the three clusters. Five-year survival rates were 83.8%, 79.3% and 91.7%, respectively. Ten-year survival rates were 75.5%, 62.9% and 83.5%, respectively. There were not statistically significant differences among the three clusters. (P = 0.119: log-rank test)

(B) Cumulative bleeding-free survival curves in the three clusters. Five-year survival rates were 98.3%, 95.1% and 97.9%, respectively. Ten-year survival rates were 98.3%, 92.2% and 92.3%, respectively. There were not statistically significant differences among

the three clusters. (P = 0.142: log-rank test)

(C) Cumulative survival curves in the 3 clusters. Five-year survival rates were 100%, 95.7% and 98.0%, respectively. Ten-year survival rates were 100%, 83.2% and 95.5%, respectively. There was statistically significant difference among the three clusters. (P = 0.0471: log-rank test)

Cluster A: secondary APS, Cluster B: accumulation of cardiovascular risks and arterial thrombosis, Cluster C: triple antiphospholipid antibody (aPL) positive and venous thrombosis.

Table 1. Characteristics of the APS patients in the 3 clusters (n=168)

Variable		All (n=168)	Cluster A (n=61)	Cluster B (n=56)	Cluster C (n=51)	P value
Age (years)	Median (range)	39 (29.5-55)	32 (25-38)	56 (50-63)	39 (25-51)	< 0.001
Observation time (months)	Median (range)	10 (5-15)	8 (3-14)	9 (5-14)	14 (7-17)	0.004
Female	n (%)	144 (85.7)	52 (85.2)	49 (87.5)	43 (84.3)	0.890
Primary APS	n (%)	63 (37.5)	15 (24.6)	26 (46.4)	22 (43.1)	0.032
APS and SLE	n (%)	98 (58.3)	44 (72.1)	27 (48.2)	27 (52.9)	0.031
APS and SS	n (%)	6 (3.6)	2 (3.3)	3 (5.4)	1 (2.0)	0.775
APS and MCTD	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
APS and RA	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Hypertension	n (%)	75 (44.6)	24 (39.3)	34 (60.7)	17 (33.3)	0.010
Dyslipidemia	n (%)	64 (38.1)	16 (26.2)	28 (50.0)	20 (39.2)	0.028
Diabetes mellitus	n (%)	23 (13.7)	6 (9.8)	11 (19.6)	6 (11.8)	0.304
Smoking	n (%)	39 (23.2)	16 (26.2)	13 (23.2)	10 (19.6)	0.742
History of arterial thrombosis	n (%)	108 (64.3)	32 (52.5)	46 (82.1)	30 (58.8)	0.002
Cerebral infarction	n (%)	92 (54.8)	25 (41.0)	39 (69.6)	28 (54.9)	0.008
Coronary heart disease	n (%)	6 (3.6)	2 (3.3)	3 (5.4)	1 (2.0)	0.775
Arterial ischaemia in legs	n (%)	5 (3.0)	3 (4.9)	1 (1.8)	1 (2.0)	0.625
Mesenteric artery occlusion	n (%)	3 (1.8)	1 (1.6)	2 (3.6)	0	0.644
Central retinal artery occlusion	n (%)	2 (1.2)	0	2 (3.6)	0	0.201
Renal infarction	n (%)	1 (0.6)	0	0	1 (2.0)	0.304
Aortic thrombosis	n (%)	1 (0.6)	1 (1.6)	0	0	1.000
History of venous thrombosis	n (%)	53 (31.5)	18 (29.5)	10 (17.9)	25 (49.0)	0.003
Deep vein thrombosis	n (%)	39 (23.2)	13 (21.3)	8 (14.3)	18 (35.3)	0.035
Pulmonary embolism	n (%)	17 (10.1)	7 (11.5)	2 (3.6)	8 (15.7)	0.089

Central retinal vein occlusion	n (%)	2 (1.2)	2 (3.3)	0	0	0.331
Superficial thrombophlebitis	n (%)	2 (1.2)	0	1 (1.8)	1 (2.0)	0.535
History of obstetric complications	n (%)	50 (34.7)	22 (42.3)	8 (16.3)	20 (46.5)	0.006
Pregnancy-induced hypertension / eclampsia	n (%)	6 (4.2)	3 (5.8)	0	3 (7.0)	0.203
Late fetal loss (≥ 10 weeks)	n (%)	28 (19.4)	10 (19.2)	7 (14.3)	11 (25.6)	0.447
Premature birth (< 34 weeks)	n (%)	4 (2.8)	0	1 (1.9)	3 (7.0)	0.072
Recurrent abortions (< 10 weeks)	n (%)	19 (13.2)	11 (21.2)	0	8 (18.6)	0.007
LA	n (%)	138 (82.1)	49 (80.3)	41 (73.2)	48 (94.1)	0.011
aCL IgG/IgM	n (%)	95 (56.5)	21 (34.4)	24 (42.9)	50 (98.0)	< 0.001
a β 2GPI IgG/IgM	n (%)	99 (58.9)	26 (42.6)	25 (44.6)	48 (94.1)	< 0.001
aPS/PT IgG/IgM	n (%)	116 (69.0)	38 (62.3)	30 (53.6)	48 (94.1)	< 0.001
Triple positive	n (%)	65 (38.7)	7 (11.5)	12 (21.4)	46 (90.2)	< 0.001
aPL-S	Mean (SD)	31.0 (25.0)	16.8 (12.4)	20.4 (16.3)	59.7 (20.2)	< 0.001

PAPS: Primary antiphospholipid syndrome, SLE: Systemic lupus erythematosus, SS: Sjögren syndrome, RA: Rheumatoid arthritis, MCTD: Mixed connective tissue disease, aPL-S: antiphospholipid antibody score,

LA: lupus anticoagulant, aCL: anticardiolipin antibody, a β 2GPI: anti- β 2Glycoprotein I antibody,

aPS/PT: phosphatidylserine dependent anti-prothrombin antibody

Triple positive: LA, IgG/M aCL and IgG/M a β 2GPI were detected at the same time

P-values < 0.05 . P-values were calculated using Kruskal-Wallis test or Fisher's Exact Test.

Table 2. Events in APS patients


Variable		All (n=168)	Cluster A (n=61)	Cluster B (n=56)	Cluster C (n=51)	P value
Events	n (%)	65 (38.7)	16 (26.2)	28 (50.0)	21 (41.2)	0.028
Events occur rate per 100 patients-year	patients-year	3.87	3.28	5.56	2.94	
Thrombosis	n (%)	47 (28.0)	14 (23.0)	19 (33.9)	14 (27.5)	0.428
Arterial thrombosis	n (%)	37 (22.0)	10 (16.4)	15 (26.8)	12 (23.5)	0.372
Cerebral infarction	n (%)	32 (19.1)	7 (11.5)	14 (25.0)	11 (21.6)	0.143
Coronary heart disease	n (%)	3 (1.8)	1 (1.6)	1 (1.8)	1 (2.0)	1.000
Central retinal artery occlusion	n (%)	1 (0.6)	1 (1.6)	0	0	1.000
Arterial ischaemia in legs	n (%)	1 (0.6)	1 (1.6)	0	0	1.000
Venous thrombosis	n (%)	10 (6.0)	4 (6.6)	4 (7.1)	2 (3.9)	0.780
Deep vein thrombosis	n (%)	8 (4.8)	4 (6.6)	2 (3.6)	2 (3.9)	0.738
Pulmonary embolism	n (%)	2 (1.2)	2 (3.3)	0	0	0.331
Central retinal vein occlusion	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Superficial thrombophlebitis	n (%)	1(0.6)	0	1 (1.8)	0	0.637
Recurrence rate per 100 patients-year	patients-year	2.80	2.87	3.77	1.96	
Severe bleeding events	n (%)	9 (5.4)	1 (1.6)	5 (8.9)	3 (5.9)	0.214
Alveolar haemorrhage	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Aortic aneurysm rupture	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Gastrointestinal haemorrhage	n (%)	2 (1.2)	0	2 (3.6)	0	0.201
Cerebral haemorrhage	n (%)	5 (3.0)	1 (1.6)	1 (1.8)	3 (5.9)	0.445
Severe bleeding rate per 100 patients-year	patients-year	0.54	0.20	0.99	0.42	
Death	n (%)	14 (8.3)	1 (1.6)	8 (14.3)	5 (9.8)	0.030
Related to thrombosis	n (%)	2 (1.2)	0	1 (1.8)	1 (2.0)	0.535

Cerebral infarction	n (%)	2 (1.2)	0	1 (1.8)	1 (2.0)	0.535
Related to bleeding	n (%)	2 (1.2)	0	2 (3.6)	0	0.201
Alveolar haemorrhage	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Aortic aneurysm rupture	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Others	n (%)	10 (6.0)	1 (1.6)	5 (8.9)	4 (7.8)	0.158
Intestinal pneumonia	n (%)	2 (1.2)	0	1 (1.8)	1 (2.0)	0.535
SLE activity	n (%)	1 (0.6)	1 (1.6)	0	0	1.000
Infection/sepsis	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Lung cancer	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Malignant lymphoma	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Amyotrophic lateral sclerosis	n (%)	1 (0.6)	0	1 (1.8)	0	0.637
Drowning	n (%)	1 (0.6)	0	0	1 (2.0)	0.304
Unknown	n (%)	2 (1.2)	0	0	2 (3.9)	0.091
Mortality per 100 patients-year	n (%)	0.83	0.20	1.59	0.70	

APS: Antiphospholipid syndrome, SLE: Systemic lupus erythematosus


P-values <0.05. P-values were calculated using Kruskal-Wallis test or Fisher's Exact Test.

Figure 1A (all)




	Follow up time (years)				
N	0	2	5	8	10
	168(0)	140(14)	112(28)	81(40)	67(48)

Figure 1B (Cluster)




	Follow up time (years)				
	0	2	5	8	10
Cluster A	61(0)	47(5)	36(9)	27(10)	22(13)
Cluster B	56(0)	46(6)	36(13)	22(20)	16(24)
Cluster C	51(0)	47(2)	40(5)	32(8)	29(11)

**Figure 2A
(Recurrent thrombosis)**




	0	4	9	10	11
Cluster A	61(0)	47(4)	35(9)	26(10)	21(11)
Cluster B	56(0)	46(4)	36(10)	23(15)	17(19)
Cluster C	51(0)	47(2)	41(3)	34(3)	32(4)

**Figure 2B
(Severe Bleeding)**



	0	1	2	3	4
Cluster A	61(0)	49(1)	40(1)	33(1)	26(1)
Cluster B	56(0)	50(0)	43(2)	31(3)	26(3)
Cluster C	51(0)	49(0)	42(2)	34(2)	31(3)

**Figure 2C
(Mortality)**



	0	0	2	3	4
Cluster A	61(0)	49(0)	40(0)	33(0)	26(0)
Cluster B	56(0)	51(0)	44(2)	32(7)	27(7)
Cluster C	51(0)	49(1)	44(2)	37(2)	34(2)